Europe Non Hodgkin Lymphoma Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
|
 CAGR |
% |
| Major Markets Players |
欧洲非霍奇金淋巴瘤诊断市场，按测试类型（成像、活检、免疫组织化学、生物标志物、基因测试、细胞遗传学、腰椎穿刺、血液测试、细胞化学等）、癌症分期（IV 期、III 期、II 期、I 期和 0 期）、肿瘤类型（侵袭性淋巴瘤和惰性淋巴瘤）、产品（基于仪器的产品、基于平台的产品、试剂盒和试剂及其他消耗品）、技术（荧光原位杂交、下一代测序、荧光免疫测定、比较基因组杂交、免疫组织化学等）、应用（筛查、诊断和预测、预后和研究）、最终用户（医院、诊断中心、癌症研究中心、学术机构、门诊手术中心等）、分销渠道（直接招标、零售等）- 行业2030 年的趋势和预测。
欧洲非霍奇金淋巴瘤诊断市场分析与洞察
欧洲对非霍奇金淋巴瘤的认识不断提高，增强了市场需求。为获得更好的医疗服务而增加的医疗支出也促进了市场的增长。在这一关键时期，主要市场参与者专注于各种服务的推出和批准。此外，诊断过程和技术的改进也促进了对非霍奇金淋巴瘤诊断测试的需求增加。
由于市场参与者的增加和先进服务的可用性，预计欧洲非霍奇金淋巴瘤诊断市场将在预测年内增长。与此同时，制造商正致力于研发活动，以在市场上推出新服务。非霍奇金淋巴瘤诊断和开发领域的研究不断增加，进一步推动了市场的增长。然而，非霍奇金淋巴瘤筛查技术的困难可能会阻碍预测期内欧洲非霍奇金淋巴瘤诊断市场的增长。
预计癌症诊断和治疗方面的医疗支出增加将为市场提供提升治疗水平的机会。然而，检测成本高昂，且癌症诊断产品审批和商业化的法规和标准严格，可能会对市场增长构成挑战。
欧洲非霍奇金淋巴瘤诊断市场具有支持性，旨在减缓疾病的进展。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，欧洲非霍奇金淋巴瘤诊断市场将以 8.2% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元）和定价（美元） |
|
涵盖的领域 |
测试类型（成像、活检、免疫组织化学、生物标志物、基因测试、细胞遗传学、腰椎穿刺、血液测试、细胞化学等）、癌症分期（IV 期、III 期、II 期、I 期和 0 期）、肿瘤类型（侵袭性淋巴瘤和惰性淋巴瘤）、产品（基于仪器的产品、基于平台的产品、试剂盒和试剂以及其他耗材）、技术（荧光原位杂交、下一代测序、荧光免疫测定、比较基因组杂交、免疫组织化学等）、应用（筛查、诊断和预测、预后和研究）、最终用户（医院、诊断中心、癌症研究中心、学术机构、门诊手术中心等）、分销渠道（直接招标、零售等） |
|
覆盖国家 |
德国、英国、法国、意大利、西班牙、俄罗斯、荷兰、瑞士、比利时、土耳其和欧洲其他地区 |
|
涵盖的市场参与者 |
佳能医疗系统株式会社（日本枥木县）、荷兰皇家飞利浦公司（荷兰阿姆斯特丹）、西门子医疗有限公司（德国埃尔朗根）、丹纳赫公司（美国华盛顿州）、Bio-Rad Laboratories, Inc（美国加利福尼亚州）、通用电气公司（美国马萨诸塞州）、Sysmex Corporation（日本兵库县）、Grail（美国加利福尼亚州）、F. Hoffmann-La Roche（瑞士巴塞尔）、东软集团（中国沈阳）、安捷伦科技公司（美国加利福尼亚州）、NeoGenomics Laboratories（美国佛罗里达州）、Hologic, Inc（美国马萨诸塞州）、Integrated DNA Technologies, Inc.、CENTOGENE NV（德国罗斯托克）、Merit Medical Systems（美国犹他州）、Invitae Corporation（美国加利福尼亚州）、PerkinElmer Inc.（美国马萨诸塞州）、QIAGEN （美国加利福尼亚州）以及 GeneDx, LLC（美国康涅狄格州）等。 |
市场定义
癌症始于淋巴，最常发生在吸烟者身上。非霍奇金淋巴瘤有两种主要类型：侵袭性非霍奇金淋巴瘤和惰性非霍奇金淋巴瘤。非霍奇金淋巴瘤的病因包括吸烟、二手烟、接触某些毒素和家族病史。
症状包括咳嗽（通常带血）、胸痛、喘息和体重减轻。这些症状通常在癌症晚期才会出现。治疗方法多种多样，但可能包括手术、化疗、放射治疗、靶向药物治疗和免疫治疗。
欧洲非霍奇金淋巴瘤诊断市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。以下内容将详细讨论所有这些内容：
- 非霍奇金淋巴瘤患病率增长
淋巴瘤是许多相关癌症亚型的统称，这些癌症源自一种名为“淋巴细胞”的白细胞。淋巴瘤分为两大类：霍奇金淋巴瘤 (HL) 和非霍奇金淋巴瘤 (NHL)。非霍奇金淋巴瘤是淋巴瘤的一个大类。有许多亚型属于这一类。弥漫性大 B 细胞淋巴瘤和滤泡性淋巴瘤是最常见的亚型。淋巴瘤癌症病例在世界各地呈上升趋势。非霍奇金淋巴瘤 (NHL) 是美国最常见的癌症之一，约占所有癌症的 4%。
男性一生中患上 NHL 的几率约为 1/43；而女性患上 NHL 的几率约为 1/53。2020 年，根据世界卫生组织 (WHO) 国际癌症研究机构的数据，全球约有 544,352 人被诊断患有非霍奇金淋巴瘤。
- 提高对非霍奇金淋巴瘤的认识
非霍奇金淋巴瘤宣传活动是提高人们对这些疾病的认识并关注其病因、预防、诊断、治疗和生存研究的机会。目的是帮助受淋巴瘤影响的人并促进健康的习惯。
全球第五大癌症是淋巴瘤，根据世界卫生组织的报告，亚洲是发病率最高的地区，过去5年共有241,270名患者，非霍奇金淋巴瘤占亚洲所有癌症死亡人数的7.4%，死亡率每年都在缓慢上升。
每年，世界各地都会举办多场宣传活动、网络研讨会和会议，向人们普及非霍奇金淋巴瘤知识，各组织也在这些活动中发挥带头作用。因此，这有望推动欧洲非霍奇金淋巴瘤诊断市场的增长。
- 缺乏训练有素、技术娴熟的医疗专业人员
卫生人员总数的密度估计为每 10,000 人口 29 人，但每 10,000 人中只有 16 人是经过培训的工作人员。对熟练和认证的专业人员的需求是欧洲非霍奇金淋巴瘤诊断市场的一个重大制约因素。由于癌症和遗传异常病例的增加，对荧光原位杂交的需求增加，但熟练专业人员数量较少预计将阻碍市场的增长。
合格的执业医师进行多项测试的能力对于医疗保健和医疗行业的发展至关重要。拥有专业团队的主要目标是确保每件救生医疗设备在最需要时都能有效发挥作用。技术人员需要接受相关制造商和机构的适当教育和认证。
技术人员面临技术培训方面的缺口，这些缺口与如何安全地采用先进方法高效执行程序有关。对于淋巴瘤的诊断，需要大量熟练的专业人员进行方法开发、验证、操作和故障排除活动
- 针对不同治疗和诊断的严格规定和指南
在这些司法管辖区销售医疗器械或药品可能需要大量的财务支出，而且可能需要数月或数年才能完成。如果不了解或考虑这些限制，延误可能会严重危及在竞争激烈的市场中取得成功的可能性。但它们在全球多个地区的批准和营销需要满足严格的监管标准并获得各监管机构的认可。
公司必须仔细审查产品规格，然后根据美国食品药品管理局 (FDA) 的规定对产品进行分类。在学术、非营利和其他生命科学研究公司中设立药物发现和开发项目需要仔细规划。每个国家都有自己的监管机构，监管机构对药物发现研究的监督很少，但提供了某些要求和明确的文件，以在此过程中实现里程碑。监管框架旨在改善获得更高质量产品的渠道，并为加强监管控制提供指导。
COVID-19 对欧洲非霍奇金淋巴瘤诊断市场的影响
COVID-19 给全球卫生保健系统带来了沉重负担，这引起了肿瘤内科医生对 COVID-19 对非霍奇金淋巴瘤诊断和治疗影响的担忧。我们在这项回顾性队列研究中调查了 COVID-19 时代之前和之后 COVID-19 对非霍奇金淋巴瘤诊断和治疗的影响。在大流行期间，新诊断的非霍奇金淋巴瘤数量减少，疾病的阶段略有增加，与 COVID-19 之前相比，放射外科手术作为第一种确定性治疗的比例显著增加，全身治疗和手术的比例均有所下降。与 COVID-19 之前相比，大流行期间开始化疗和放射治疗没有明显延迟。
然而，在疫情期间，我们观察到非霍奇金淋巴瘤手术有所延迟。COVID-19 似乎对我们非霍奇金淋巴瘤中心的非霍奇金淋巴瘤患者的诊断和治疗模式产生了重大影响。许多肿瘤学家担心，未来一年新诊断的非霍奇金淋巴瘤患者的数量将会增加。这项研究仍在进行中，我们将收集和分析更多信息，以更好地了解 COVID-19 疫情对我们的非霍奇金淋巴瘤患者群体的总体影响。
近期发展
- 2022 年 11 月，丹纳赫宣布与杜克大学建立战略合作伙伴关系，成立首个丹纳赫基因治疗创新灯塔项目。该项目投资于产品创新，以推进外部研发战略，重点关注基因组药物、精准诊断、下一代生物制造、人体系统和数据科学。
- 2022 年 8 月，Bio-Rad Laboratories Inc. 收购了 Curiosity Diagnostics，这是一家总部位于波兰的医疗诊断和医疗保健市场创新技术解决方案开发商。此举帮助该公司扩大了其产品组合并扩大了其在欧洲市场的份额。
欧洲非霍奇金淋巴瘤诊断市场细分
欧洲非霍奇金淋巴瘤诊断市场分为八个显著的细分市场，根据检测类型、癌症分期、肿瘤类型、产品、技术、应用、最终用户和分销渠道划分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
按测试类型
- 影像学
- 活检
- 免疫组织化学
- 生物标志物测试
- 基因检测
- 细胞遗传学
- 腰椎穿刺（脊椎穿刺）
- 验血
- 细胞化学
- 其他的
根据癌症分期
- 第 0 阶段
- 第一阶段
- 第二阶段
- 第三阶段
- 第四阶段
按肿瘤类型
- 侵袭性淋巴瘤
- 惰性淋巴瘤
按产品
- 基于仪器的产品
- 基于平台的产品
- 试剂盒和试剂
- 其他耗材
按技术分类
- 荧光原位杂交
- 下一代测序
- 荧光免疫分析法
- 比较基因组杂交
- 免疫组织化学
- 其他的
按应用
- 筛查
- 诊断和预测
- 预测
- 研究
由最终用户
- 医院
- 诊断中心
- 癌症研究中心
- 学术机构
- 门诊手术中心
- 其他的
按分销渠道
- 直接招标
- 零售销售
- 其他的
欧洲非霍奇金淋巴瘤诊断市场区域分析/见解
对欧洲非霍奇金淋巴瘤诊断市场进行了分析，并按上述测试类型、癌症阶段、肿瘤类型、产品、技术、应用、最终用户、分销渠道提供了市场规模洞察和趋势。
非霍奇金淋巴瘤诊断报告涵盖的国家包括德国、法国、英国、意大利、西班牙、荷兰、俄罗斯、瑞士、土耳其、奥地利、挪威、匈牙利、立陶宛、爱尔兰、波兰和欧洲其他地区。
由于医疗服务技术的不断提高和可靠性的提高以及信息娱乐服务的提供，德国在欧洲非霍奇金淋巴瘤诊断市场占据主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析以及案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在对国家数据进行预测分析时，还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和欧洲非霍奇金淋巴瘤诊断市场份额分析
欧洲非霍奇金淋巴瘤诊断市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、欧洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对非霍奇金淋巴瘤诊断市场的关注有关。
市场上的一些主要参与者包括佳能医疗系统公司、荷兰皇家飞利浦公司、西门子医疗有限公司、丹纳赫、Bio-Rad Laboratories, Inc.、通用电气公司、Sysmex Corporation、Grail、F. Hoffmann-La Roche、东软集团、安捷伦科技公司、NeoGenomics Laboratories、Hologic, Inc、Integrated DNA Technologies, Inc.、CENTOGENE NV、Merit Medical Systems、Invitae Corporation、PerkinElmer Inc.、QIAGEN 和 GeneDx, LLC 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 INDUSTRY INSIGHTS
6 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA
7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA
7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA
7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP
7.2 RESTRAINTS
7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS
7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS
7.3 OPPORTUNITIES
7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS
7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D
7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS
7.4 CHALLENGES
7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE
7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT
7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL)
8 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 IMAGING
8.2.1 COMPUTED TOMOGRAPHY (CT)
8.2.2 CHEST X-RAY
8.2.3 MAGNETIC RESONANCE IMAGING (MRI)
8.2.4 ULTRASOUND
8.2.5 POSITRON EMISSION TOMOGRAPHY (PET)
8.3 BIOPSY
8.3.1 EXCISIONAL OR INCISIONAL BIOPSY
8.3.2 CORE NEEDLE BIOPSY
8.4 IMMUNOHISTOCHEMISTRY
8.5 BIOMARKER TEST
8.5.1 BETA 2-M
8.5.2 LDH
8.5.3 CA-125
8.5.4 TP53
8.5.5 NPM1
8.5.6 OTHERS
8.6 GENETIC TEST
8.7 CYTOGENETICS
8.8 LUMBAR PUNCTURE (SPINAL TAP)
8.9 BLOOD TEST
8.1 CYTOCHEMISTRY
8.11 OTHERS
9 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE
9.1 OVERVIEW
9.2 AGGRESSIVE LYMPHOMAS
9.2.1 DIFFUSE LARGE B CELL LYMPHOMA
9.2.1.1 INSTRUMENT BASED PRODUCTS
9.2.1.2 PLATFORM BASED PRODUCTS
9.2.1.3 KITS AND REAGENTS
9.2.1.4 OTHER CONSUMABLES
9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA
9.2.2.1 INSTRUMENT BASED PRODUCTS
9.2.2.2 PLATFORM BASED PRODUCTS
9.2.2.3 KITS AND REAGENTS
9.2.2.4 OTHER CONSUMABLES
9.2.3 MANTLE CELL LYMPHOMA
9.2.3.1 INSTRUMENT BASED PRODUCTS
9.2.3.2 PLATFORM BASED PRODUCTS
9.2.3.3 KITS AND REAGENTS
9.2.3.4 OTHER CONSUMABLES
9.2.4 PERIPHERAL T-CELL LYMPHOMA
9.2.4.1 INSTRUMENT BASED PRODUCTS
9.2.4.2 PLATFORM BASED PRODUCTS
9.2.4.3 KITS AND REAGENTS
9.2.4.4 OTHER CONSUMABLES
9.2.5 LYMPHOBLASTIC LYMPHOMA
9.2.5.1 INSTRUMENT BASED PRODUCTS
9.2.5.2 PLATFORM BASED PRODUCTS
9.2.5.3 KITS AND REAGENTS
9.2.5.4 OTHER CONSUMABLES
9.2.6 BURKITT LYMPHOMA
9.2.6.1 INSTRUMENT BASED PRODUCTS
9.2.6.2 PLATFORM BASED PRODUCTS
9.2.6.3 KITS AND REAGENTS
9.2.6.4 OTHER CONSUMABLES
9.3 INDOLENT LYMPHOMAS
9.3.1 FOLLICULAR LYMPHOMA
9.3.1.1 INSTRUMENT BASED PRODUCTS
9.3.1.2 PLATFORM BASED PRODUCTS
9.3.1.3 KITS AND REAGENTS
9.3.1.4 OTHER CONSUMABLES
9.3.2 CUTANEOUS T-CELL LYMPHOMA
9.3.2.1 INSTRUMENT BASED PRODUCTS
9.3.2.2 PLATFORM BASED PRODUCTS
9.3.2.3 KITS AND REAGENTS
9.3.2.4 OTHER CONSUMABLES
9.3.3 MARGINAL ZONE B CELL LYMPHOMA
9.3.3.1 INSTRUMENT BASED PRODUCTS
9.3.3.2 PLATFORM BASED PRODUCTS
9.3.3.3 KITS AND REAGENTS
9.3.3.4 OTHER CONSUMABLES
9.3.4 LYMPHOPLASMACYTIC LYMPHOMA
9.3.4.1 INSTRUMENT BASED PRODUCTS
9.3.4.2 PLATFORM BASED PRODUCTS
9.3.4.3 KITS AND REAGENTS
9.3.4.4 OTHER CONSUMABLES
9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA
9.3.5.1 INSTRUMENT BASED PRODUCTS
9.3.5.2 PLATFORM BASED PRODUCTS
9.3.5.3 KITS AND REAGENTS
9.3.5.4 OTHER CONSUMABLES
10 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 SCREENING
10.2.1 INSTRUMENT BASED PRODUCTS
10.2.2 PLATFORM BASED PRODUCTS
10.2.3 KITS AND REAGENTS
10.2.4 OTHER CONSUMABLES
10.3 DIAGNOSTIC AND PREDICTIVE
10.3.1 INSTRUMENT BASED PRODUCTS
10.3.2 PLATFORM BASED PRODUCTS
10.3.3 KITS AND REAGENTS
10.3.4 OTHER CONSUMABLES
10.4 PROGNOSTIC
10.4.1 INSTRUMENT BASED PRODUCTS
10.4.2 PLATFORM BASED PRODUCTS
10.4.3 KITS AND REAGENTS
10.4.4 OTHER CONSUMABLES
10.5 RESEARCH
10.5.1 INSTRUMENT BASED PRODUCTS
10.5.2 PLATFORM BASED PRODUCTS
10.5.3 KITS AND REAGENTS
10.5.4 OTHER CONSUMABLES
11 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE
11.1 OVERVIEW
11.2 STAGE IV
11.3 STAGE I
11.4 STAGE III
11.5 STAGE II
11.6 STAGE 0
12 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY
12.1 OVERVIEW
12.2 FLUORESCENT IN SITU HYBRIDIZATION
12.3 NEXT GENERATION SEQUENCING
12.4 FLUORIMMUNOASSAY
12.5 COMPARATIVE GENOMIC HYBRIDIZATION
12.6 IMMUNOHISTOLOCHEMICAL
12.7 OTHER
13 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT
13.1 OVERVIEW
13.2 INSTRUMENT BASED PRODUCTS
13.2.1 IMAGING
13.2.2 BIOPSY
13.3 PLATFORM BASED PRODUCTS
13.3.1 NEXT-GENERATION SEQUENCING
13.3.2 MICROARRAYS
13.3.3 PCR
13.3.4 OTHERS
13.4 KITS AND REAGENTS
13.4.1 NON-HODGKIN LYMPHOMA PANELS
13.4.2 IMMUNOHISTOCHEMISTRY STAINS
13.4.3 OTHERS
13.5 OTHER CONSUMABLES
14 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DIAGNOSTIC CENTERS
14.4 CANCER RESEARCH CENTERS
14.5 ACADEMIC INSTITUTES
14.6 AMBULATORY SURGICAL CENTERS
14.7 OTHERS
15 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.4 OTHERS
16 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION
16.1 EUROPE
16.1.1 GERMANY
16.1.2 UNITED KINGDOM
16.1.3 FRANCE
16.1.4 ITALY
16.1.5 SPAIN
16.1.6 RUSSIA
16.1.7 NETHERLANDS
16.1.8 SWITZERLAND
16.1.9 BELGIUM
16.1.10 TURKEY
16.1.11 REST OF EUROPE
17 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: EUROPE
18 SWOT ANALYSIS
19 EUROPE NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET
19.1 CANON MEDICAL SYSTEMS CORPORATION
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 KONINKLIJKE PHILIPS N.V.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 SIEMENS HEALTHCARE GMBH
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 DANAHER.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 BIO-RAD LABORATORIES, INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 AGILENT TECHNOLOGIES, INC.
19.6.1 COMPANY PROFILE
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 CENTOGENE N.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 F. HOFFMANN- LA ROCHE LTD
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 GENERAL ELECTRIC COMPANY
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 GENEDX, LLC
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 GRAIL
19.11.1 COMPANY PROFILE
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 HOLOGIC INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 INVITAE CORPORATION
19.13.1 COMPANY PROFILE
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENT
19.14 NEUSOFT CORPORATION
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENT
19.15 NEOGENOMICS LABORATORIES
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 PERKINELMER INC
19.16.1 COMPANY PROFILE
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 QIAGEN
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENT
19.18 SYSMEX CORPORATION
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 3 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE IMMUNOHISTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE GENETIC TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE CYTOGENETICS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 EUROPE LUMBAR PUNCTURE (SPINAL TAP) IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE BLOOD TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE CYTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 16 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 18 EUROPE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 19 EUROPE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 20 EUROPE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 21 EUROPE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 22 EUROPE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 23 EUROPE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 24 EUROPE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 26 EUROPE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 27 EUROPE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 EUROPE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 29 EUROPE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 30 EUROPE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 31 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 34 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 36 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 38 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 40 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 41 EUROPE STAGE IV IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE STAGE I IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE STAGE III IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE STAGE II IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION
TABLE 45 EUROPE STAGE 0 IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 47 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE NEXT GENERATION SEQUENCING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE FLUORIMMUNOASSAY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 EUROPE IMMUNOHISTOCHEMICAL IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 54 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 56 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 58 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 60 EUROPE OTHER CONSUMABLES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION))
TABLE 61 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 62 EUROPE HOSPITALS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 EUROPE DIAGNOSTIC CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 EUROPE CANCER RESEARCH CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 EUROPE ACADEMIC INSTITUTES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 EUROPE AMBULATORY SURGICAL CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 67 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 68 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 69 EUROPE DIRECT TENDER IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 70 EUROPE RETAIL SALES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 71 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 72 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 73 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 78 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 79 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 80 EUROPE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 81 EUROPE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 82 EUROPE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 83 EUROPE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 84 EUROPE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 EUROPE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 86 EUROPE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 87 EUROPE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 EUROPE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 89 EUROPE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 90 EUROPE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 91 EUROPE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 92 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 95 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 96 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 97 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 98 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 99 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 100 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 101 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 102 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 103 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 104 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 105 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 106 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 107 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 108 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 109 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 110 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 111 GERMANY IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 GERMANY BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 GERMANY BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 114 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 115 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 116 GERMANY AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 117 GERMANY DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 118 GERMANY ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 119 GERMANY MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 120 GERMANY PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 121 GERMANY LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 122 GERMANY BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 GERMANY INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 124 GERMANY FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 125 GERMANY CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 126 GERMANY MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 127 GERMANY LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 128 GERMANY SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 129 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 130 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 131 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 132 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 133 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 134 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 135 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 136 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 137 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 138 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 139 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 140 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 141 GERMANY SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 142 GERMANY DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 GERMANY PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 144 GERMANY RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 145 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 146 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 147 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 148 UNITED KINGDOM IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 149 UNITED KINGDOM BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 150 UNITED KINGDOM BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 151 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 152 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 153 UNITED KINGDOM AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 154 UNITED KINGDOM DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 155 UNITED KINGDOM ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 156 UNITED KINGDOM MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 157 UNITED KINGDOM PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 158 UNITED KINGDOM LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 159 UNITED KINGDOM BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 160 UNITED KINGDOM INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 161 UNITED KINGDOM FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 162 UNITED KINGDOM CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 163 UNITED KINGDOM MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 164 UNITED KINGDOM LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 165 UNITED KINGDOM SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 166 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 167 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 168 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 169 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 170 UNITED KINGDOM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 171 UNITED KINGDOM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 172 UNITED KINGDOM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 173 UNITED KINGDOM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 174 UNITED KINGDOM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 175 UNITED KINGDOM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 176 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 177 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 178 UNITED KINGDOM SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 179 UNITED KINGDOM DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 180 UNITED KINGDOM PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 UNITED KINGDOM RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 183 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 184 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 185 FRANCE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 FRANCE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 187 FRANCE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 188 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 189 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 190 FRANCE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 191 FRANCE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 192 FRANCE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 193 FRANCE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 194 FRANCE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 195 FRANCE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 196 FRANCE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 197 FRANCE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 198 FRANCE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 199 FRANCE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 200 FRANCE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 201 FRANCE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 202 FRANCE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 203 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 204 FRANCE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 205 FRANCE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 206 FRANCE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 207 FRANCE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 208 FRANCE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 209 FRANCE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 210 FRANCE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 211 FRANCE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 212 FRANCE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 213 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 214 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 FRANCE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 216 FRANCE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 217 FRANCE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 218 FRANCE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 219 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 220 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 221 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 222 ITALY IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 223 ITALY BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 ITALY BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 225 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 226 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 227 ITALY AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 228 ITALY DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 229 ITALY ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 230 ITALY MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 231 ITALY PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 232 ITALY LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 233 ITALY BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 234 ITALY INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 235 ITALY FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 236 ITALY CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 237 ITALY MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 238 ITALY LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 ITALY SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 240 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 241 ITALY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 242 ITALY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 243 ITALY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 244 ITALY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 245 ITALY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 246 ITALY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 247 ITALY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 248 ITALY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 249 ITALY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 250 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 251 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 252 ITALY SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 253 ITALY DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 254 ITALY PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 255 ITALY RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 256 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 257 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 258 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 259 SPAIN IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 260 SPAIN BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 261 SPAIN BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 262 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 263 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 264 SPAIN AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 265 SPAIN DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 266 SPAIN ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 267 SPAIN MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 268 SPAIN PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 269 SPAIN LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 270 SPAIN BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 271 SPAIN INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 272 SPAIN FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 273 SPAIN CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 274 SPAIN MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 275 SPAIN LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 276 SPAIN SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 277 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 278 SPAIN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 279 SPAIN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 280 SPAIN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 281 SPAIN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 282 SPAIN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 283 SPAIN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 284 SPAIN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 285 SPAIN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 286 SPAIN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 287 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 288 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 289 SPAIN SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 290 SPAIN DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 291 SPAIN PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 292 SPAIN RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 293 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 294 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 295 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 296 RUSSIA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 297 RUSSIA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 298 RUSSIA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 299 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 300 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 301 RUSSIA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 302 RUSSIA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 303 RUSSIA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 304 RUSSIA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 305 RUSSIA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 306 RUSSIA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 307 RUSSIA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 308 RUSSIA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 309 RUSSIA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 310 RUSSIA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 311 RUSSIA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 312 RUSSIA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 313 RUSSIA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 314 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 315 RUSSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 316 RUSSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 317 RUSSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 318 RUSSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 319 RUSSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 320 RUSSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 321 RUSSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 322 RUSSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 323 RUSSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 324 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 325 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 326 RUSSIA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 327 RUSSIA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 328 RUSSIA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 329 RUSSIA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 330 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 331 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 332 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 333 NETHERLANDS IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 334 NETHERLANDS BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 335 NETHERLANDS BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 336 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 337 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 338 NETHERLANDS AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 339 NETHERLANDS DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 340 NETHERLANDS ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 341 NETHERLANDS MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 342 NETHERLANDS PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 343 NETHERLANDS LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 344 NETHERLANDS BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 345 NETHERLANDS INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 346 NETHERLANDS FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 347 NETHERLANDS CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 348 NETHERLANDS MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 349 NETHERLANDS LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 350 NETHERLANDS SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 351 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 352 NETHERLANDS INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 353 NETHERLANDS INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 354 NETHERLANDS INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 355 NETHERLANDS PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 356 NETHERLANDS PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 357 NETHERLANDS PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 358 NETHERLANDS KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 359 NETHERLANDS KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 360 NETHERLANDS KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 361 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 362 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 363 NETHERLANDS SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 364 NETHERLANDS DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 365 NETHERLANDS PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 366 NETHERLANDS RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 367 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 368 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 369 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 370 SWITZERLAND IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 371 SWITZERLAND BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 372 SWITZERLAND BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 373 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 374 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 375 SWITZERLAND AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 376 SWITZERLAND DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 377 SWITZERLAND ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 378 SWITZERLAND MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 379 SWITZERLAND PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 380 SWITZERLAND LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 381 SWITZERLAND BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 382 SWITZERLAND INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 383 SWITZERLAND FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 384 SWITZERLAND CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 385 SWITZERLAND MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 386 SWITZERLAND LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 387 SWITZERLAND SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 388 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 389 SWITZERLAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 390 SWITZERLAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 391 SWITZERLAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 392 SWITZERLAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 393 SWITZERLAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 394 SWITZERLAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 395 SWITZERLAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 396 SWITZERLAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 397 SWITZERLAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 398 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 399 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 400 SWITZERLAND SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 401 SWITZERLAND DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 402 SWITZERLAND PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 403 SWITZERLAND RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 404 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 405 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 406 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 407 BELGIUM IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 408 BELGIUM BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 409 BELGIUM BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 410 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 411 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 412 BELGIUM AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 413 BELGIUM DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 414 BELGIUM ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 415 BELGIUM MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 416 BELGIUM PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 417 BELGIUM LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 418 BELGIUM BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 419 BELGIUM INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 420 BELGIUM FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 421 BELGIUM CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 422 BELGIUM MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 423 BELGIUM LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 424 BELGIUM SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 425 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 426 BELGIUM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 427 BELGIUM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 428 BELGIUM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 429 BELGIUM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 430 BELGIUM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 431 BELGIUM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 432 BELGIUM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 433 BELGIUM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 434 BELGIUM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 435 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 436 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 437 BELGIUM SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 438 BELGIUM DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 439 BELGIUM PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 440 BELGIUM RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 441 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 442 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 443 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 444 TURKEY IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 445 TURKEY BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 446 TURKEY BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 447 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 448 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 449 TURKEY DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 450 TURKEY ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 451 TURKEY MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 452 TURKEY PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 453 TURKEY LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 454 TURKEY BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 455 TURKEY INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 456 TURKEY FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 457 TURKEY CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 458 TURKEY MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 459 TURKEY LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 460 TURKEY SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 461 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 462 TURKEY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 463 TURKEY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 464 TURKEY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 465 TURKEY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 466 TURKEY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 467 TURKEY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 468 TURKEY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 469 TURKEY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 470 TURKEY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 471 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 472 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 473 TURKEY SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 474 TURKEY DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 475 TURKEY PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 476 TURKEY RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 477 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 478 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 479 REST OF EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 10 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 12 THE INCREASING PREVALENCE OF NON-HODGKIN LYMPHOMA AND INCREASED RESEARCH & DEVELOPMENT IN NON-HODGKIN LYMPHOMA DIAGNOSTICS ARE DRIVING THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET
FIGURE 15 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2022
FIGURE 16 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 17 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 18 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 19 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2022
FIGURE 20 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION)
FIGURE 21 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, CAGR (2023-2030)
FIGURE 22 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, LIFELINE CURVE
FIGURE 23 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2022
FIGURE 24 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 25 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 26 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2022
FIGURE 28 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION)
FIGURE 29 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030)
FIGURE 30 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE
FIGURE 31 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2022
FIGURE 32 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 33 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 34 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 35 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2022
FIGURE 36 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 37 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 38 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 39 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2022
FIGURE 40 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 41 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)
FIGURE 42 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 44 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 45 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 46 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 48 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 49 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 52 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
